Fed. Circ. To Revisit Ariad, Lilly IP Dispute En Banc
A federal appeals court has granted Ariad Pharmaceuticals Inc.'s request for an en banc rehearing in its patent infringement suit against Eli Lilly & Co. over the drugs Evista and Xigris,...To view the full article, register now.
Already a subscriber? Click here to view full article